Search clinical trials for: Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS)

Total 474247 results

Otsuka Pharmaceutical Development & Commercialization...

Completed

Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Substudy 'B' of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1) (OSMITTER)

Device Latency

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)

Multidrug Resistant Tuberculosis

Philippines, South Africa
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia

Schizophrenia
Maastricht University Medical Center
VieCuri Medical Centre; CEP Group Holding B.V.; Campus Venlo

Completed

Effect of MOF on Exercise Blood Pressure

Healthy

Netherlands
University of Birmingham
AstraZeneca; Cancer Trials Ireland

Active, not recruiting

CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC) (CompARE)

Oropharyngeal Cancer

United Kingdom, Ireland
Otsuka Pharmaceutical Development & Commercialization...

Completed

Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1) (OSMITTER)

Device Latency

United States
Medical University of South Carolina

Active, not recruiting

Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Prostate Cancer

United States
Rigshospitalet, Denmark

Completed

Ex Vivo 3D-ultrasound for Oropharyngeal Cancer

Oropharyngeal Squamous Cell Carcinoma

Denmark
Bial - Portela C S.A.

Completed

Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)

Parkinson Disease

United Kingdom
Kyowa Kirin Co., Ltd.

Completed

A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes, Type 2

Japan
Otsuka America Pharmaceutical

Completed

A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma

HIV Infections | Sarcoma, Kaposi

United States
Bial - Portela C S.A.

Completed

Efficacy and Safety of Opicapone in Clinical Practice (OPTIPARK)

Parkinson's Disease With Wearing-off Motor Fluctuations

Germany
University of Rochester

Completed

Parallel Group, Placebo-Controlled, Tolerability, Safety, and Efficacy Study of OPC-14117 in HIV Dementia

HIV Infections | Cognitive Disorders

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity

Schizophrenia With Impulsivity

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)

Cardiac Edema

Japan
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)

Stress Disorders, Post-Traumatic

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia

Schizophrenia

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)

Oropharyngeal Cancer | HPV-Related Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Withdrawn

Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability

Major Depressive Disorder and Irritability

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole

Nervous System Diseases | Schizophrenia | Mental Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Withdrawn

Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder

Nervous System Diseases | Schizophrenia | Mental Disorder | Bipolar 1 Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission

Ulcerative Colitis

United States
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

Metastatic Pancreatic Ductal Adenocarcinoma

United States, China, Hungary, Taiwan, Belgium, Germany, Spain, Italy, Czechia, France, Japan, Switzerland, Australia, Israel, Korea, Republic of, Canada, Russian Federation, Slovakia, United Kingdom, Turkey, Sweden, Greece, Finland, ... and more
Otsuka Pharmaceutical Development & Commercialization...

Completed

The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder

Adult Attention Deficit Hyperactivity Disorder

United States
University College, London
Society for Cardiothoracic Surgery in Great Britain & Ireland; British Congenital...

Unknown

National Congenital Heart Disease Audit

Congenital Heart Disease (CHD)

United Kingdom
Otsuka Pharmaceutical Development & Commercialization...

Completed

Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease

Netherlands
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]

Autosomal Dominant Polycystic Kidney Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis

Chronic Renal Failure

Japan
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms

Anxiety | Major Depressive Disorder

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Japan
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S; Otsuka America Pharmaceutical

Completed

Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia

Schizophrenia

United States, Croatia, Latvia
Otsuka Pharmaceutical Co., Ltd.

Completed

A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)

Cardiac Edema

Japan
Royal North Shore Hospital

Not yet recruiting

De-escalation of Radiation Dose in HPV-associated OPC Utilising FMISO PET (DE-RADIATE) (DE-RADIATE)

HPV Positive Oropharyngeal Squamous Cell Carcinoma

Australia
Otsuka Beijing Research Institute

Recruiting

OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects

Open Angle Glaucoma or Ocular Hypertension

China
Otsuka Pharmaceutical Development & Commercialization...
Quintiles, Inc.

Completed

Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia (EQUATOR)

Acute Schizophrenia

United States, Malaysia, Serbia, Ukraine, Romania, Puerto Rico, Colombia, Turkey
Otsuka Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Japan
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Autosomal Recessive Polycystic Kidney Disease (ARPKD)

United States, Belgium, Spain, Germany, United Kingdom, Poland
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S; Otsuka America Pharmaceutical

Completed

Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia

Schizophrenia

United States, Croatia, Latvia
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

Schizophrenia

United States
Otsuka America Pharmaceutical

Completed

A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons

HIV Infections

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

Evaluation Study of the Bioavailability of Brexpiprazole Orally Disintegrating Tablets in Healthy Male Subjects

Healthy Adult Male

Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

Tolvaptan Extension Study in Participants With ADPKD (TEMPO 4/4)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States, Australia, Belgium, Germany, Italy, Poland, Romania, United Kingdom, Argentina, Canada, France, Netherlands, Russian Federation
Otsuka Pharmaceutical Development & Commercialization...

Completed

Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

Polycystic Kidney, Autosomal Dominant

Belgium, Germany, Italy, Spain, Sweden, United States, Canada, Australia, Netherlands, Czechia, Poland, Denmark, Israel, Hungary, Russian Federation, South Africa, United Kingdom, Romania, Argentina, Norway
Bial - Portela C S.A.

Completed

Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules

Parkinson

Canada
Otsuka Pharmaceutical Co., Ltd.

Completed

Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Agitation Associated With Dementia of the Alzheimer's Type

Japan
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders

ADHD | Conduct Disorder | Oppositional Defiant Disorder | Autism | Bipolar I Disorder

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study of OPC-41061 Orally Disintegrating (OD) Tablets Using 2 Different Formulations and 2 Dosing Regimens in Healthy Adult Male Subjects

Healthy Adult Male

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)

Carcinomatous Edema

Japan
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (TEMPO 2:4)

Polycystic Kidney, Autosomal Dominant

United States

Search clinical trials for: Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations